Calidi director files initial Form 3

Calidi Biotherapeutics, Inc. director Sanders Corazon (Corsee) D. filed an initial Form 3, which is a statement of beneficial ownership for company insiders.

Rhea-AI Filing Summary

Calidi Biotherapeutics, Inc. director Sanders Corazon (Corsee) D. filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This excerpt shows no reported transactions or derivative positions, indicating the filing is focused on establishing reporting status rather than documenting trades.

Key Terms

Form 3, reporting person, beneficial ownership

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [ { "name": "Sanders Corazon (Corsee) D.""

beneficial ownership financial

"initial statement of beneficial ownership for company insiders"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Calidi Biotherapeutics (CLDI) Form 3 filing show?

The Form 3 lists director Sanders Corazon (Corsee) D. as a reporting person at Calidi Biotherapeutics. In this excerpt, no transactions, holdings, or derivative positions are reported, so it serves mainly to establish insider reporting status.

Who is the reporting person in the Calidi Biotherapeutics (CLDI) Form 3?

The reporting person is Sanders Corazon (Corsee) D., identified as a director of Calidi Biotherapeutics, Inc. This status means future changes in beneficial ownership generally must be reported on subsequent insider forms such as Form 4 or Form 5.

Does the Calidi Biotherapeutics (CLDI) Form 3 report any share transactions?

No transactions are reported in this Form 3 excerpt. All transaction-related counts, including buys, sells, exercises, gifts, and tax withholdings, are listed as zero, indicating no trades or ownership changes are disclosed here.

Are any derivative securities disclosed in the Calidi Biotherapeutics (CLDI) Form 3?

No derivative securities are disclosed in this excerpt. The derivativeSummary is empty and derivativeTransactionCount is zero, so there is no reported options, warrants, or other derivative activity associated with the director in this dataset.

What is the purpose of a Form 3 for Calidi Biotherapeutics (CLDI) insiders?

Form 3 is the initial statement of beneficial ownership for insiders such as directors at Calidi Biotherapeutics. It establishes who must report future changes in ownership, which are typically disclosed later on Forms 4 or 5 when transactions occur.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 05:12 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sanders Corazon (Corsee) D.

(Last) (First) (Middle)

C/O CALIDI BIOTHERAPEUTICS, INC.

4475 EXECUTIVE DRIVE, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/17/2026

3. Issuer Name and Ticker or Trading Symbol
Calidi Biotherapeutics, Inc. [ CLDI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Corazon (Corsee) D. Sanders	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)